title: Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
abstract: Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. There may be a role for ECP in the treatment of refractory early stage MF, but data are limited.
authors.affiliation: Division of Dermatology, Vanderbilt University School of Medicine, 701 Thompson Ln, Ste 26300, Nashville, TN 37204, USA. Electronic address: john.zic@vanderbilt.edu.
authors.forename: John A
authors.initials: JA
authors.lastname: Zic
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D056747:Immunomodulation; D008730:Methoxsalen / Q000493:pharmacokinetics / Q000627:therapeutic use; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000401:mortality; D017893:Photopheresis / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000401:mortality; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017319:Photosensitizing Agents; D008730:Methoxsalen
keywords: Cutaneous T-cell lymphoma; Extracorporeal photopheresis; Mycosis fungoides; Photochemotherapy; Sézary syndrome